These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8969284)

  • 21. Evidence for a hypothalamic-pituitary versus adrenal cortical effect of glycemic control on counterregulatory hormone responses to hypoglycemia in insulin-dependent diabetes mellitus.
    Kinsley BT; Simonson DC
    J Clin Endocrinol Metab; 1996 Feb; 81(2):684-91. PubMed ID: 8636289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
    Glaser B; Leibovich G; Nesher R; Hartling S; Binder C; Cerasi E
    Acta Endocrinol (Copenh); 1988 Jul; 118(3):365-73. PubMed ID: 3293339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the beta cell and arterial hyperinsulinemia.
    Bolli G; De Feo P; Perriello G; De Cosmo S; Compagnucci P; Santeusanio F; Brunetti P; Unger RH
    J Clin Invest; 1984 Apr; 73(4):917-22. PubMed ID: 6368593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group.
    Am J Med; 1991 Apr; 90(4):450-9. PubMed ID: 2012085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.
    Wolffenbuttel BH; Menheere PP; Nijst L; Rondas-Colbers GJ; Sels JP; Nieuwenhuijzen Kruseman AC
    Neth J Med; 1992 Jun; 40(5-6):277-82. PubMed ID: 1436266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
    Ahrén B; Larsson H; Holst JJ
    J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of glyburide on in vivo insulin-mediated glucose disposal.
    Simonson DC
    Am J Med; 1990 Aug; 89(2A):44S-50S; discussion 51S-53S. PubMed ID: 2117389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recovery of epinephrine response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetes.
    Davis M; Mellman M; Friedman S; Chang CJ; Shamoon H
    Am J Med; 1994 Dec; 97(6):535-42. PubMed ID: 7985713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial.
    Fanelli CG; Pampanelli S; Porcellati F; Rossetti P; Brunetti P; Bolli GB
    Ann Intern Med; 2002 Apr; 136(7):504-14. PubMed ID: 11926785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to neuroglycopenia: an adaptive response during intensive insulin treatment of diabetes.
    Jones TW; Borg WP; Borg MA; Boulware SD; McCarthy G; Silver D; Tamborlane WV; Sherwin RS
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1713-8. PubMed ID: 9177369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased peripheral venous somatostatin concentration and decreased glucagon response to arginine in patients with insulin dependent diabetes mellitus without residual B-cell function. Increased plasma SRIF in IDDM.
    Skare S; Dahl-Jørgensen K; Hanssen KF; Norman N
    Acta Endocrinol (Copenh); 1985 Aug; 109(4):517-21. PubMed ID: 2863913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients.
    Simonson DC; Delprato S; Castellino P; Groop L; DeFronzo RA
    Diabetes; 1987 Feb; 36(2):136-46. PubMed ID: 3100365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study).
    Pozzilli P; Visalli N; Cavallo MG; Signore A; Baroni MG; Buzzetti R; Fioriti E; Mesturino C; Fiori R; Romiti A; Giovannini C; Lucentini L; Matteoli MC; Crinò A; Teodonio C; Paci F; Amoretti R; Pisano L; Suraci C; Multari G; Suppa M; Sulli N; De Mattia G; Faldetta MR
    Eur J Endocrinol; 1997 Sep; 137(3):234-9. PubMed ID: 9330586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.
    Bougnères PF; Landais P; Boisson C; Carel JC; Frament N; Boitard C; Chaussain JL; Bach JF
    Diabetes; 1990 Oct; 39(10):1264-72. PubMed ID: 2210078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of treatment protocols in the Diabetes Control and Complications Trial.
    Diabetes Care; 1995 Mar; 18(3):361-76. PubMed ID: 7555480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic Characteristics of Recently Diagnosed Adult-Onset Autoimmune Diabetes Mellitus.
    Zaharia OP; Bobrov P; Strassburger K; Bódis K; Karusheva Y; Scholz M; Markgraf DF; Burkart V; Schloot NC; Müssig K; Szendroedi J; Roden M;
    J Clin Endocrinol Metab; 2018 Feb; 103(2):429-437. PubMed ID: 29220505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term intensive therapy of IDDM patients with clinically overt autonomic neuropathy: effects on hypoglycemia awareness and counterregulation.
    Fanelli C; Pampanelli S; Lalli C; Del Sindaco P; Ciofetta M; Lepore M; Porcellati F; Bottini P; Di Vincenzo A; Brunetti P; Bolli GB
    Diabetes; 1997 Jul; 46(7):1172-81. PubMed ID: 9200653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.